Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: Predicting l-DOPA-induced dyskinesia

Behavioural Brain Research

Volumn 226, Issue 1, 2012, Pages 281-292

  Smith, Gaynor A ^a   Heuer, Andreas ^a   Dunnett, Stephen B ^a   Lane, Emma L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

5 HT; 6 Hydroxydopamine; Dyskinesia; FosB; L 3,4 dihydroxyphenylalanine; TH

Indexed keywords

APOMORPHINE; BENSERAZIDE; LEVODOPA; OXIDOPAMINE; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DYSKINESIA; LOCOMOTION; MEDIAL FOREBRAIN BUNDLE; MOTOR PERFORMANCE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA; VISUOMOTOR COORDINATION;

ADRENERGIC AGENTS; ANIMALS; APOMORPHINE; CORPUS STRIATUM; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MICE; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA;

EID: 80053608158     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.09.025     Document Type: Article

References (54)

1. Sharma J.C., Bachmann C.G., Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2010, 16:490-497.
2. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968, 5:107-110.
3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
4. Bordet R., Destee A. From Parkinson's disease to Lewy body disease. Presse Med 1992, 21:708-712.
5. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
6. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998, 10:2694-2706.
7. Steece-Collier K., Collier T.J., Danielson P.D., Kurlan R., Yurek D.M., Sladek J.R. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord 2003, 18:1442-1454.
8. Allbutt H.N., Henderson J.M. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods 2007, 159:195-202.
9. Baird A.L., Meldrum A., Dunnett S.B. The staircase test of skilled reaching in mice. Brain Res Bull 2001, 54:243-250.
10. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
11. Dowd E., Monville C., Torres E.M., Dunnett S.B. The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 2005, 68:24-30.
12. Dunnett S.B., Torres E.M., Annett L.E. A lateralised grip strength test to evaluate unilateral nigrostriatal lesions in rats. Neurosci Lett 1998, 246:1-4.
13. Francardo V., Recchia A., Popovic N., Andersson D., Nissbrandt H., Cenci M.A. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to l-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 2011, 42(3):327-340.
14. Grealish S., Mattsson B., Draxler P., Bjorklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010, 31:2266-2278.
15. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
16. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16:110-123.
17. Heuer A, Smith GA, Lelos MJ, Lane EL, Dunnett SB. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice. I. Behavioural assessment of dopamine depletion targeting three different lesion sites. Behav Brain Res; Unpublished results.
18. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci 2007, 25. [chapter 9: unit 9].
19. Paille V., Brachet P., Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport 2004, 15:561-564.
20. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002, 10:165-186.
21. Lundblad M., Usiello A., Carta M., Hakansson K., Fisone G., Cenci M.A. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005, 194:66-75.
22. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 2003, 84:1398-1410.
23. Mandel R.J., Randall P.K. Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the mouse. Brain Res 1985, 330:358-363.
24. Randall P.K. Lesion-induced DA supersensitivity in aging C57BL/6J mice. Brain Res 1984, 308:333-336.
25. Smith G.A., Heuer A. 6-OHDA toxin models of PD in mice. Contemporary animal models with movement disorders 2011, Springer/Humana, UK. E.L. Lane, S.B. Dunnett (Eds.).
26. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
27. Monville C., Torres E.M., Dunnett S.B. Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J Neurosci Method 2006, 158:219-223.
28. Smith G.A., Murphy E., Dunnett S.B., Lane E.L. Induced animal models of Parkinson's disease 2011, CRC Press, London, (chapter 5).
29. Montoya C.P., Campbell-Hope L.J., Pemberton K.D., Dunnett S.B. The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991, 36:219-228.
30. Westin J.E., Andersson M., Lundblad M., Cenci M.A. Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci 2001, 14:1171-1176.
31. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol Dis 2009, 35:42-51.
32. Dowd E., Dunnett S.B. Deficits in a lateralized associative learning task in dopamine-depleted rats with functional recovery by dopamine-rich transplants. Eur J Neurosci 2004, 20:1953-1959.
33. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946, 94:239-247.
34. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010, 68:619-628.
35. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain: J Neurol 2007, 130:1819-1833.
36. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983, 275:321-328.
37. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999, 6:461-474.
38. Andersson M., Westin J.E., Cenci M.A. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 2003, 17:661-666.
39. Valastro B., Andersson M., Lindgren H.S., Cenci M.A. Expression pattern of JunD after acute or chronic l-DOPA treatment: comparison with deltaFosB. Neuroscience 2007, 144:198-207.
40. Brenhouse H.C., Stellar J.R. c-Fos and deltaFosB expression are differentially altered in distinct subregions of the nucleus accumbens shell in cocaine-sensitized rats. Neuroscience 2006, 137:773-780.
41. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15:120-132.
42. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995, 195:195-198.
43. Olds M.E., Jacques D.B., Kopyov O. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra subregions. Synapse 2006, 59:532-544.
44. Gil S., Park C., Lee J., Koh H. The roles of striatal serotonin and l-amino-acid decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. Cell Mol Neurobiol 2010, 30:817-825.
45. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M., et al. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 2003, 343:17-20.
46. Rozas G., Liste I., Guerra M.J., Labandeira-Garcia J.L. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998, 245:151-154.
47. Zhou F.C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res 1991, 556:108-116.
48. Winkler J.D., Weiss B. Reversal of supersensitive apomorphine-induced rotational behavior in mice by continuous exposure to apomorphine. J Pharmacol Exp Ther 1986, 238:242-247.
49. Huot P., Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 2007, 101:1441-1447.
50. Darmopil S., Muneton-Gomez V.C., de Ceballos M.L., Bernson M., Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by l-DOPA. Eur J Neurosci 2008, 27:580-592.
51. Mazloom M., Smith Y. Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Comp Neurol 2006, 495:453-469.
52. Tande D., Hoglinger G., Debeir T., Freundlieb N., Hirsch E.C., Francois C. New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. Brain: J Neurol 2006, 129:1194-1200.
53. Jollivet C., Montero-Menei C.N., Venier-Julienne M.C., Sapin A., Benoit J.P., Menei P. Striatal tyrosine hydroxylase immunoreactive neurons are induced by l-dihydroxyphenylalanine and nerve growth factor treatment in 6-hydroxydopamine lesioned rats. Neurosci Lett 2004, 362:79-82.
54. Mura A., Feldon J., Mintz M. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and l-DOPA treatment. Exp Neurol 2000, 164:322-332.